Answers are grounded in this paper and cite their sources.
Background Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of metastatic renal cell carcinoma (mRCC) and combination regimens with targeted therapy are the current standard of care. Given their success in the first-line setting, re-use or continuation of ICIs in subsequent line settings has been a growing area of research interest. Objective This systematic review assesses the safety and efficacy of ICI re-challenge in patients with refractory mRCC. Methods Scopus, Embase, Cochrane, Ovid MEDLINE, and TRIP databases as well as clinicaltrials.gov were searched systematically for published prospective and upcoming clinical trials from inception to August 15, 2023. Inclusion criteria included patients with clear cell histology who had received at least one prior line of systemic therapy including an ICI. Trials with ICI as an intervention either in second-line or beyond were included and did not require a control arm. Safety and efficacy outcomes including overall response rates, overall survival, progression free survival, median duration of response, and grade 3 or higher adverse events (AEs) were extracted. Results Seven prospective studies and 49 upcoming clinical trials were identified. mPFS ranged from 3.7 to 12.2 months, with longer PFS rates being associated with ICI/VEGF combination re-challenge. However, data from the only phase III randomized controlled trial (CONTACT-03) did not support rechallenge of ICI with tyrosine kinase inhibitor (TKI) versus TKI alone. Rates of grade 3 or higher AEs ranged from 28–65%. Conclusions Given the paucity of current data regarding efficacy as well as high toxicity rates, patients with mRCC should not receive ICI-rechallenge unless as part of a prospective clinical trial.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: